Seelos Therapeutics Inc. (SEEL)’s Financial Results Comparing With Sol-Gel Technologies Ltd. (NASDAQ:SLGL)

This is therefore a comparing of the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation in Seelos Therapeutics Inc. (NASDAQ:SEEL) and Sol-Gel Technologies Ltd. (NASDAQ:SLGL). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seelos Therapeutics Inc. 1 0.00 21.93M -6.17 0.00
Sol-Gel Technologies Ltd. 11 0.00 6.22M -1.66 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Seelos Therapeutics Inc. and Sol-Gel Technologies Ltd.


Table 2 demonstrates the return on equity, return on assets and net margins of Seelos Therapeutics Inc. and Sol-Gel Technologies Ltd.

Net Margins Return on Equity Return on Assets
Seelos Therapeutics Inc. 1,740,890,688.26% 0% -435.1%
Sol-Gel Technologies Ltd. 56,700,091.16% 0% 0%


The Current Ratio and Quick Ratio of Seelos Therapeutics Inc. are 2.9 and 2.9 respectively. Its competitor Sol-Gel Technologies Ltd.’s Current Ratio is 7.8 and its Quick Ratio is 7.8. Sol-Gel Technologies Ltd. can pay off short and long-term obligations better than Seelos Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for Seelos Therapeutics Inc. and Sol-Gel Technologies Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Seelos Therapeutics Inc. 0 0 1 3.00
Sol-Gel Technologies Ltd. 0 0 2 3.00

Seelos Therapeutics Inc.’s upside potential is 39.86% at a $2 average target price. Competitively Sol-Gel Technologies Ltd. has an average target price of $25, with potential upside of 78.95%. Based on the analysts opinion we can conclude, Sol-Gel Technologies Ltd. is looking more favorable than Seelos Therapeutics Inc.

Institutional & Insider Ownership

Seelos Therapeutics Inc. and Sol-Gel Technologies Ltd. has shares held by institutional investors as follows: 15% and 15.3%. Insiders held 18.48% of Seelos Therapeutics Inc. shares. Comparatively, insiders own roughly 79.39% of Sol-Gel Technologies Ltd.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Seelos Therapeutics Inc. 24.4% 19.75% -15.08% -55.04% -87.81% -81.42%
Sol-Gel Technologies Ltd. 0.84% 4.5% 2.08% -8.43% 25.34% 38.87%

For the past year Seelos Therapeutics Inc. had bearish trend while Sol-Gel Technologies Ltd. had bullish trend.


Sol-Gel Technologies Ltd. beats on 6 of the 9 factors Seelos Therapeutics Inc.

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.